You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Recent advances of novel targeted therapy in non-small cell lung cancer
|
|---|---|
| Published in |
Journal of Hematology & Oncology, January 2009
|
| DOI | 10.1186/1756-8722-2-2 |
| Pubmed ID | |
| Authors |
Jed A Katzel, Michael P Fanucchi, Zujun Li |
| Abstract |
Lung cancer is the leading cause of cancer deaths world-wide. Recent advances in cancer biology have led to the identification of new targets in neoplastic cells and the development of novel targeted therapies. At this time, two targeted agents are approved by the FDA in advanced non-small cell lung cancer (NSCLC): the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib, and the anitangiogenic bevacizumab. A third agent, cetuximab, which was recently shown to enhance survival when used with cisplatin and vinorelbine as first line therapy for advanced NSCLC, will likely be approved by regulatory agencies. With more than 500 molecularly targeted agents under development, the prospects of identifying novel therapies that benefit individual patients with lung cancer are bright. |
Mendeley readers
The data shown below were compiled from readership statistics for 105 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Korea, Republic of | 1 | <1% |
| Italy | 1 | <1% |
| Unknown | 103 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 20 | 19% |
| Researcher | 15 | 14% |
| Student > Bachelor | 13 | 12% |
| Student > Master | 11 | 10% |
| Other | 8 | 8% |
| Other | 19 | 18% |
| Unknown | 19 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 29 | 28% |
| Agricultural and Biological Sciences | 22 | 21% |
| Biochemistry, Genetics and Molecular Biology | 14 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 6% |
| Chemistry | 5 | 5% |
| Other | 10 | 10% |
| Unknown | 19 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 November 2022.
All research outputs
#7,611,089
of 23,206,358 outputs
Outputs from Journal of Hematology & Oncology
#514
of 1,204 outputs
Outputs of similar age
#50,077
of 172,075 outputs
Outputs of similar age from Journal of Hematology & Oncology
#4
of 8 outputs
Altmetric has tracked 23,206,358 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,204 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.4. This one has gotten more attention than average, scoring higher than 51% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 172,075 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 19th percentile – i.e., 19% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one. This one has scored higher than 4 of them.